Impel NeuroPharma, Inc.
201 Elliott Avenue West, Suite 260
Seattle, WA 98119
September 7, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Dillon Hagius | |
| Re: | Impel NeuroPharma, Inc. Registration Statement on Form S-1 (File No. 333-259363) originally filed September 7, 2021 |
Requested Date: September 9, 2021
Requested Time: 4:30 PM Eastern Time
Ladies and Gentlemen:
Impel NeuroPharma, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statement on Form S-1effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Amanda L. Rose or Alan C. Smith, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Rose at (206) 389-4553, or, in her absence, Mr. Smith at (206) 389-4530.
* * *
| Sincerely, | ||
| IMPEL NEUROPHARMA, INC. | ||
| By: | /s/ John Leaman | |
| John Leaman | ||
| Chief Financial Officer | ||
| cc: | Adrian Adams, President and Chief Executive Officer |
John Leaman, M.D., Chief Financial Officer
Impel NeuroPharma, Inc.
Alan Smith, Esq.
Amanda L. Rose, Esq.
Ryan Mitteness, Esq.
Fenwick & West LLP
[Signature Page to Company Acceleration Request Letter]
